This trial is active, not recruiting.

Condition solid tumors
Treatment s-3304
Phase phase 1
Sponsor Shionogi
Start date November 2001
End date October 2003
Trial size 28 participants
Trial identifier NCT00033215, 0110P1416


To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Eligibility Criteria

Male or female participants from 18 years up to 85 years old.

Inclusion criteria: - Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s) - Must be able to tolerate oral medication Exclusion criteria - Patients with other serious illnesses - Patients who are receiving treatments

Additional Information

Official title A Phase 1 Study of S-3304 in Patients With Solid Tumors
Trial information was received from ClinicalTrials.gov and was last updated in June 2005.
Information provided to ClinicalTrials.gov by Shionogi.